Retatrutide and Ibuprofen Nsaids Interaction: Evidence and Limits
A research-focused answer to "Retatrutide and Ibuprofen Nsaids Interaction: Evidence and Limits". What the evidence can establish, its limits, and retatrutide's investigational status.
FormBlends Editorial Research · Updated 2026-09-27
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Mechanisms do not validate a combination
Different receptor targets can suggest a hypothesis, but they do not establish that combining substances improves outcomes or is safe. Retatrutide activates GIP, GLP-1 and glucagon receptors. That description does not establish a safe combination with another peptide, prescription medicine or supplement.
A useful combination study would specify the actual products, participant population, comparator, clinical outcomes and adverse events. Evidence for each ingredient separately, animal experiments, or a plausible biological explanation is not evidence for the combined regimen in people. The sources cited here do not establish the combination raised by this page as an approved treatment.
Absence of a reported interaction is not proof that no interaction exists. These research limitations do not support instructions about spacing medicines, changing another prescription, stacking peptides or selecting a combination dose.
How to evaluate a claim about this topic
The question "Retatrutide and Ibuprofen Nsaids Interaction: Evidence and Limits" needs evidence that matches the actual claim. Identify the named study, the population enrolled and the outcome measured. Check whether the result was prespecified, whether there was a relevant comparator, and whether the report includes harms as well as benefits. The studies linked below provide context; they do not establish every claim implied by this question.
Sources
Ibuprofen with retatrutide: what is known
Can I safely take ibuprofen while on retatrutide, and does it change absorption?
- A PubMed search pairing GLP-1 drugs with NSAIDs found 23 papers and 0 randomized controlled trials, so nothing answers whether ibuprofen is safe with retatrutide. FDA also says retatrutide has not been found safe and effective for any condition. [PubMed search counts]
- Absorption is unanswered too. The phase 2 retatrutide trial in type 2 diabetes (NCT04867785) reported average blood levels of retatrutide at each dose. That outcome measured retatrutide levels, not ibuprofen levels, so it says nothing about ibuprofen absorption. [ClinicalTrials.gov NCT04867785 results]
- Reports on related drugs do not name ibuprofen. In FAERS, 730 of 181,068 tirzepatide reports (0.40%) and 344 of 78,023 semaglutide reports (0.44%) list 'drug interaction'. These are shares of reports, not risk, and they say nothing about NSAIDs. [openFDA drug adverse event endpoint (FAERS)]
- Gastric emptying is the closest absorption-related term in the data. FAERS lists 'impaired gastric emptying' in 1.0% of tirzepatide reports and 5.4% of semaglutide reports. Those shares do not mention ibuprofen and do not show any change in how it is absorbed. [openFDA drug adverse event endpoint (FAERS)]
- Vomiting and dehydration appear among the overdose effects FDA lists from dosing errors, and an exenatide case report describes severe vomiting followed by kidney injury. The data do not show whether ibuprofen changes that. [FDA alert on dosing errors with compounded injectable semaglutide]
Sources: PubMed search counts, topic search with humans[mh], animals[mh] and randomized controlled trial[pt] filters (accessed 2026-11-17); ClinicalTrials.gov NCT04867785 results (accessed 2026-11-17); openFDA drug adverse event endpoint (FAERS), patient.drug.openfda.generic_name and reactionmeddrapt.exact counts (accessed 2026-11-16); FDA alert on dosing errors with compounded injectable semaglutide (accessed 2026-11-17)
How much research covers GLP-1 drugs and NSAIDs
The search found 23 papers and no randomized trials.
Each bar counts papers found by one PubMed search; a count says how much research exists, not what it concluded.
See the numbers
| Papers | |
|---|---|
| All papers on this topic | 23 |
| Tagged as human studies | 19 |
| Animal studies only | 3 |
| Randomized controlled trials | 0 |
PubMed search run 2026-11-17: (retatrutide OR tirzepatide OR semaglutide OR GLP-1 receptor agonist) AND (ibuprofen OR nonsteroidal anti-inflammatory drug OR NSAID) AND (drug interaction OR absorption OR gastric emptying OR kidney). Tags are added by PubMed indexers and new papers may not be tagged yet.
Source: PubMed search counts, topic search with humans[mh], animals[mh] and randomized controlled trial[pt] filters (accessed 2026-11-17)
The closest papers
Neither paper tests retatrutide with ibuprofen, so they offer context only.
- Health records analysis7,856 peopleBMC Endocr Disord, 2024
Predicting responsiveness to GLP-1 pathway drugs using real-world data
Vanderbilt records of people with type 2 diabetes on GLP-1 pathway drugs showed that women under 40 who also took NSAIDs had a larger HbA1c drop (0.82% vs 0.28%). This is an association about blood sugar, not about safety or absorption, and it does not involve retatrutide.
- Case reportJ Ayub Med Coll Abbottabad, 2014
Exenatide induced acute kidney injury
A 47-year-old woman developed severe vomiting, low blood pressure, acute kidney injury and lactic acidosis one week after starting exenatide, and needed emergency dialysis. She also took an ACE inhibitor and a diuretic. She had no recent NSAID use, so the case says nothing about combining the two.
Findings are summarized from each paper's abstract.
Source: PubMed, abstracts of the papers listed (accessed 2026-11-17)